Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
CASI
#3956
CASI Pharmaceuticals, Inc. Ordinary Shares
0.2
1
-73.75%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
-73.75%
Monthly Change
-78.79%
6 month change
-90.41%
Year Change
-91.36%
Previous Close
0.8
0
Open
0.2
1
Bid
Ask
Low
0.2
1
High
0.2
1
Volume
17
Markets
US Stock Market
Healthcare
CASI
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
15.49 M
—
Valuation ratios
Enterprise value
30.34 M
—
Price to earnings ratio
-1.11
—
Price to sales ratio
—
—
Price to cash flow ratio
-1.49
—
Price to book ratio
23.45
—
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
0.51
—
Return on equity %
14.92
—
Return on invested capital %
-12.38
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
0.94
—
Current ratio
1.09
—
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
0.35
—
Long term debt to total equity ratio
10.21
—
Per share metrics
Operating cash flow per share
1.91
—
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
0.99
—
Net current asset value per share
2.58
—
Tangible book value per share
0.11
—
Working capital per share
0.2
—
Book value per share
0.12
—
News
What Drove CASI Pharmaceuticals' 24% Rise After Hours? - CASI Pharmaceuticals (NASDAQ:CASI)
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.63%
CASI Pharmaceuticals stock plunges on Nasdaq delisting notice
Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year?
Are Medical Stocks Lagging Alkermes (ALKS) This Year?
China approves CASI Pharmaceuticals’ CID-103 clinical trial for kidney rejection
CASI Pharmaceuticals stock surges after Nasdaq grants listing extension
Casi Pharmaceuticals secures Nasdaq listing extension until February 2026
CASI Pharmaceuticals secures $20 million funding for transplant rejection study
CASI Pharmaceuticals reports positive phase 1 data for ITP treatment
CASI Pharmaceuticals faces Nasdaq delisting over market value requirement
James Huang to join CASI Pharmaceuticals board as independent director